We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. As Healio previously reported, more than 90% of ...

Please provide your email address to receive an email when new articles are posted on . Most adults with acromegaly maintained or improved IGF-I levels with oral octreotide in three phase 3 trials.

Researchers at the Medical University of South Carolina revealed the need to clarify current treatment guidelines for octreotide therapy following an esophageal variceal hemorrhage in a recent study ...

Syringe and Vials To date, the Company has not received any reports of adverse reactions related to this recall. Mylan Institutional LLC, a Viatris Company, has voluntarily recalled 1 lot of ...

Chiasma is a small-cap biotech focusing on developing of oral formulation of the existing drug for acromegaly (octreotide) and attacking a $810m market. The company received CRL from FDA in 2016 due ...

October 12, 2012 (Montreal, Quebec) — In a finding described as both surprising and practice-changing, octreotide (Sandostatin, Novartis) showed no benefit over less expensive, more accessible ...

A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract ...

MUMBAI, Aug 17 (Reuters) - Indian drug maker Sun Pharmaceutical Industries Ltd. has received approval from the U.S. Food and Drug Administration to make and market octreotide injection, the ...

An open-label, multicenter, randomized phase II study of atezolizumab and bevacizumab with Y90 TARE in patients with unresectable hepatocellular carcinoma (HCC). Background: Somatostatin receptor ...

(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), announced the launch of the first and only generic version of Sandostatin LAR Depot, in the United States.